700 Technology Square, Floor 2
About Inozyme Pharma
Inozyme Pharma is a biotechnology company committed to developing novel medicines for the treatment of rare diseases characterized by mineral imbalances, which lead to over calcification of soft tissues and under mineralization of bone. The company was founded in 2016 with technology licensed from Yale University.
Co-Founder, President & CEO: Axel Bolte
Sr. VP & COO: Henric Bjarke
Sr. VP & CTO: Steven Jungles
Sr. VP & CMO: Erin Yuen
VP, Regulatory and Government Affairs: Ruhi Ahmed
VP, Finance: Stephen Basso
Please click here for Inozyme Pharma's science.
Please click here for Inozyme Pharma's job opportunities.
13 articles with Inozyme Pharma
10/16/2020Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs
Upsized IPO in July 2020 raised $128.8 million in gross proceeds Submitted IND for INZ-701 for the treatment of ENPP1 deficiency; currently on FDA clinical hold pending completion of ongoing GLP toxicology studies Initiation of INZ-701 Phase 1/2 clinical trials anticipated in early 2021, as previously planned BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of di
Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, today announced the closing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $16.00 per share on July 28, 2020 and the closing of the sale of 1,050,000 additional shares of common stock on July 30, 2020 following the exercise in f
Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $112.0 million,
Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today the appointment of Doug Treco, Ph.D., as Chairman of the Company’s Board of Directors
Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency
Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization impacting the vasculature, soft tissue and skeleton, and GACI Global ( www.gaciglobal.org ), a patient advocacy organization dedicated to bettering the lives of families affected by Generalized Arterial Calcification of Infancy and/or Autosomal Recessive Hypophosphatemic Rickets Type 2 (GACI/A
Strengthens Inozyme’s Ability to Advance Lead Candidate, INZ-701, into Clinical Trials
Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders
Financing to Advance Lead Development Program, INZ-701, through Clinical Proof of Concept in Two Indications
Novel Enzyme Replacement Therapy in Development for Treatment of ENPP1 Deficiency
Inozyme Pharma (Inozyme), today introduced a no-cost, third-party genetic testing program designed to improve detection and understanding of two rare calcification disorders.
Inozyme Pharma Appoints David Thompson, Ph.D., as Senior Vice President and Chief Scientific Officer
Inozyme Pharma is a biopharmaceutical company dedicated to developing treatments for rare and debilitating metabolic diseases
The $49M in Series A funding will be used to develop the company's enzyme replacement therapies for two rare diseases affecting infants and children and push the treatments into the clinic.